UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 2.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,072,296 shares of the insurance provider's stock after selling 21,480 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.89% of Humana worth $425,937,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Montag A & Associates Inc. grew its stake in Humana by 1,880.0% during the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider's stock worth $25,000 after buying an additional 94 shares during the last quarter. Johnson Financial Group Inc. purchased a new stake in Humana in the second quarter valued at approximately $26,000. Fideuram Asset Management Ireland dac acquired a new stake in shares of Humana in the fourth quarter valued at approximately $27,000. Trust Co. of Vermont acquired a new stake in shares of Humana in the second quarter valued at approximately $28,000. Finally, Reflection Asset Management purchased a new position in shares of Humana during the fourth quarter worth approximately $29,000. 92.38% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on HUM. Bank of America raised shares of Humana from a "neutral" rating to a "buy" rating and set a $500.00 target price on the stock in a report on Wednesday, July 29th. UBS Group initiated coverage on shares of Humana in a research note on Thursday, July 30th. They set a "buy" rating for the company. Lake Street Capital initiated coverage on shares of Humana in a research report on Thursday, July 30th. They set a "buy" rating on the stock. HSBC cut shares of Humana to a "hold" rating in a report on Thursday, July 30th. Finally, Cantor Fitzgerald increased their target price on shares of Humana from $264.00 to $300.00 and gave the stock a "neutral" rating in a research note on Tuesday, July 7th. Fourteen analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $403.91.
View Our Latest Analysis on HUM
Humana Price Performance
Humana stock opened at $386.92 on Monday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.74 and a quick ratio of 1.74. The business has a 50 day simple moving average of $385.60 and a 200-day simple moving average of $289.17. Humana Inc. has a 12 month low of $163.11 and a 12 month high of $428.88. The stock has a market capitalization of $46.46 billion, a PE ratio of 36.61, a price-to-earnings-growth ratio of 2.20 and a beta of 0.72.
Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share for the quarter, beating analysts' consensus estimates of $7.27 by $0.34. The firm had revenue of $40.89 billion for the quarter, compared to analyst estimates of $40.58 billion. Humana had a net margin of 0.88% and a return on equity of 11.20%. Humana's quarterly revenue was up 26.2% on a year-over-year basis. During the same period last year, the firm posted $6.27 EPS. Equities analysts predict that Humana Inc. will post 9.12 earnings per share for the current year.
Humana Company Profile
(
Free Report)
Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
Further Reading
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
